SecBot SecBot
8-K ·Filed May 26, 2026

CGON

CG Oncology, Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-237908
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor the Chief Commercial Officer search and any updates on commercial strategy execution. No immediate trading catalyst from this organizational change.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$61.89
T+0 close · May 26, 2026 · via day close
Latest settled
+30.36%
T+60 · $80.68
Vs SPY
+27.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $61.89entry
  2. T+1 · 6mo ago −1.76%α −1.77% · $60.80
  3. T+5 · 6mo ago −4.30%α −5.38% · $59.23
  4. T+20 · 5mo ago +13.50%α +15.45% · $70.25
  5. T+60 · 3mo ago +30.36%α +27.64% · $80.68
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology announced the departure of President & COO Ambaw Bellete, effective June 30, 2026, and appointed CEO Arthur Kuan as President in addition to his existing roles. The company has initiated a search for a Chief Commercial Officer. This is a routine executive reorganization with no material financial impact.

Key Facts

  • President & COO Ambaw Bellete agreed to separation effective June 30, 2026
  • CEO Arthur Kuan appointed as President in addition to his current positions
  • Company initiated search for a Chief Commercial Officer
  • Bellete will receive severance benefits per existing employment agreement

Financial Impact

No financial figures disclosed; severance is contractual and routine

Risk Factors

  • Potential disruption from COO departure during commercial build-out
  • Key-person concentration risk as CEO adds President role

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-237908
Document: 0001193125-26-237908-index-headers.html0001193125-26-237908
Document: 0001193125-26-237908-index.html0001193125-26-237908
Document: 0001193125-26-237908.txt0001193125-26-237908

Track record

25 reports on CGON

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026